Partners' Directory

  Home   Search   Join the Partnership   Login

Contact General Specializations in Countries Contribution to the Global Plan Declaration

View this partner's profile

Organization Contact Information

Name: Treatment Action Group
Street 1: 261 5th Ave, Suite 2110
Street 2:
City: New York
Province: NY
Post Code: 10016
Country: United States of America
Phone: 2122537922
Email: tag@treatmentactiongroup.org
Web Site: http://www.treatmentactiongroup.org

Focal Point Contact Information

Salutation: Ms.
First Name: Erica
Last Name: Lessem
Title: TB/HIV Project Director
Email: erica.lessem@treatmentactiongroup.org
Phone: +1 212 253 7922

Alternate Focal Point Contact Information

Salutation: Mr
First Name: Mike
Last Name: Frick
Title: TB/HIV Project Officer
Email: mike.frick@treatmentactiongroup.org
Phone: +1 212 253 7922

General Information

Board Constituency: Developed Country NGO
Organization Type - Primary: Non-Governmental Organization
Organization Type - Secondary: Community-Based Organization (CBO)
Is your organization legally registered in your country: Yes
Organization Reach: International
Organization Description:
TAG is a community-based HIV/AIDS research and treatment advocacy organization with focus areas in basic science, immunology, antiretroviral drug development, community education and mobilization, and TB/HIV.
 
Total number of staff in your organization: 6 - 10
Number of full-time staff who are directly involved with TB: 1 - 5
Number of part-time staff who are directly involved with TB: 1 - 5
Number of volunteers who are directly involved with TB: 0
 
What is your organization's annual budget (USD) dedicated to TB? $500,001-$1 MIL
How did you hear about the Stop TB Partnership: Other partners
If you were informed or referred by another partner of the Stop TB Partnership please tell us who:
Why do you wish join the Stop TB Partnership: Involvement in Stop TB Working Groups
 
Are you a member of a Stop TB national partnership: No
Are you in contact with your national TB programme: Yes
Please tell us how your organization is contributing to your country's national TB control plan:
Through supporting the CDC's TB Research Trial Consortium, participating in national policy development through the Advisory Council on the Elimination of TB, and increasing support for TB programs and research within the US national budget.
 

Geographical Reach

Which country is your headquarters located in: United States of America
Which WHO region is the main focus of your work: American
Which countries do you do operate in:
(This includes countries you are conducting activities in)
United States of America

Specializations

Advocacy

Specializations in Countries

Advocacy United States of America

Contribution

Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:

Drug-Resistant TB:
Monitoring the development and scale-up of diagnostics and treatment for drug-resistant TB and assessing the contributions of key stakeholders including, national leadership, the Global Laboratory Initiative, and the Global Drug Facility towards the scale up of DR-TB treatment.

TB-HIV:
Advocacy for the scale-up for of TB/HIV collaborative services. TAG participates on the TB/HIV Working Group and works to ensure that new tools being developed are effective in addressing TB in people with HIV.

New Diagnostics:
Monitoring the pipeline of new TB diagnostics and advocating for increased research and a comprehensive TB diagnostics portfolio. Tracking resources available for R&D for TB diagnostics and comparing them against the targets set by the Global Plan to Stop TB 2011-2015.

New TB Drugs:
Monitoring the pipeline of new TB drugs and advocating for increased research and a comprehensive TB drugs portfolio. Tracking resources available for R&D for TB drugs compared to the targets set by the Global Plan to Stop TB 2011-2015. TAG participates in the Stakeholders Association of the New TB Drugs Working Group.

New TB Vaccines:
Monitoring the pipeline of new TB vaccines and advocating for increased research and a comprehensive TB vaccines portfolio. Tracking resources available for R&D for TB vaccines compared to the targets set by the Global Plan to Stop TB 2011-2015.

Fundamental Research:
Monitoring fundamental TB research and advocating for increased research, increased research funding, and a comprehensive TB fundamental research portfolio. Tracking resources available for TB fundamental research compared to the targets set by the Global Plan to Stop TB 2011-2015.

Research:
Monitoring TB operational research and advocating for increased research to improve programmatic implementation. Tracking resources available for TB operational research compared to the targets set by the Global Plan to Stop TB 2011-2015.

Declaration

Declaration of interests:
N/A.

Application date:  
Last updated: August 17, 2015